Precursor B-Cell Acute Lymphoblastic Leukemia
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Precursor B-Cell Acute Lymphoblastic Leukemia is an emerging landscape with 18 programs across 14 companies. The most active players are Eastern Cooperative Oncology Group, Amgen, Teva.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
75%
Small molecule
12 of 16 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.
Analysis
Trial Status
1
clinical trials
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)